Esperovax, Ginkgo Bioworks Join Hands To Develop Circular RNA-based Therapeutics

Esperovax, a developer of oral mRNA biologics, and Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, Thursday announced a partnership to develop circular RNAs for a variety of therapeutic applications.

Initially, Ginkgo and Esperovax would work to develop circRNAs harboring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells.

Read Full Article ->